Clarity Pharmaceuticals Ltd (CU6)

Currency in AUD
1.780
+0.010(+0.56%)
Closed·
CU6 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.7201.790
52 wk Range
1.6855.140
Key Statistics
Bid/Ask
1.745 / 1.78
Prev. Close
1.77
Open
1.74
Day's Range
1.72-1.79
52 wk Range
1.685-5.14
Volume
2.13M
Average Volume (3m)
2.16M
1-Year Change
-63.2231%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CU6 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.195
Upside
+304.21%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.195
(+304.21% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy8.38+370.79%8.41MaintainSep 16, 2026

Earnings

Latest Release
Aug 27, 2026
EPS / Forecast
-0.14 / 27.10
Revenue / Forecast
4.72M / 31M
EPS Revisions
Last 90 days

CU6 Income Statement

Compare CU6 to Peers and Sector

Metrics to compare
CU6
Peers
Sector
Relationship
P/E Ratio
−6.2x−2.8x−0.3x
PEG Ratio
0.14−0.040.00
Price/Book
3.6x2.6x2.6x
Price / LTM Sales
63.1x5.9x2.9x
Upside (Analyst Target)
304.2%52.2%64.0%
Fair Value Upside
Unlock10.0%7.8%Unlock

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
34.36M9.21%61.50M
Other Institutional Investors
121.12M32.46%216.80M
Public Companies & Retail Investors
217.61M58.33%389.51M
Total
373.08M100.00%667.82M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
State Street Investment Management5.25%19,603,85135,091
JPMorgan Chase & Co.4.90%18,273,46832,710

People Also Watch

2.050
SLS
-2.38%
1.800
PYC
+1.12%
0.715
TCG
-4.67%
196.08
CSL
-0.11%
1.520
DRO
+2.01%

FAQ

What Is the Clarity Pharmaceuticals (CU6) Stock Price Today?

The Clarity Pharmaceuticals stock price today is 1.780 AUD.

What Stock Exchange Does Clarity Pharmaceuticals Trade On?

Clarity Pharmaceuticals is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for Clarity Pharmaceuticals?

The stock symbol for Clarity Pharmaceuticals is "CU6."

What Is the Clarity Pharmaceuticals Market Cap?

As of today, Clarity Pharmaceuticals market cap is 660.350M AUD.

What Is Clarity Pharmaceuticals's Earnings Per Share (TTM)?

The Clarity Pharmaceuticals EPS (TTM) is -0.29.

From a Technical Analysis Perspective, Is CU6 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Clarity Pharmaceuticals Stock Split?

Clarity Pharmaceuticals has split 0 times.

How Many Employees Does Clarity Pharmaceuticals Have?

Clarity Pharmaceuticals has 100 employees.

What is the current trading status of Clarity Pharmaceuticals (CU6)?

As of Oct 21, 2026, Clarity Pharmaceuticals (CU6) is trading at a price of 1.780 AUD, with a previous close of 1.770 AUD. The stock has fluctuated within a day range of 1.720 AUD to 1.790 AUD, while its 52-week range spans from 1.685 AUD to 5.140 AUD.

What Is Clarity Pharmaceuticals (CU6) Price Target According to Analysts?

The average 12-month price target for Clarity Pharmaceuticals is 7.195 AUD, with a high estimate of 8.4 AUD and a low estimate of 5.6 AUD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +304.21% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.